Show simple item record

dc.contributor.authorOladimeji, O
dc.contributor.authorIsaakidis, P
dc.contributor.authorObasanya, O J
dc.contributor.authorEltayeb, O
dc.contributor.authorKhogali, M
dc.contributor.authorVan den Bergh, R
dc.contributor.authorKumar, A M V
dc.contributor.authorHinderaker, S G
dc.contributor.authorAbdurrahman, S T
dc.contributor.authorLawson, L
dc.contributor.authorCuevas, L E
dc.date.accessioned2014-04-15T16:02:24Z
dc.date.available2014-04-15T16:02:24Z
dc.date.issued2014-04
dc.identifier.citationIntensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria. 2014, 9 (4):e94393 PLoS ONEen_GB
dc.identifier.issn1932-6203
dc.identifier.pmid24722139
dc.identifier.doi10.1371/journal.pone.0094393
dc.identifier.urihttp://hdl.handle.net/10144/315844
dc.description.abstractNigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them.
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permissionen_GB
dc.subjectAntibiotic Resistanceen_GB
dc.subjectTuberculosisen_GB
dc.subjectCourse on Operational Researchen_GB
dc.subjectHIV/AIDSen_GB
dc.titleIntensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeriaen
dc.identifier.journalPLoS Oneen_GB
refterms.dateFOA2019-03-04T11:13:19Z
html.description.abstractNigeria is faced with a high burden of Human Immunodeficiency Virus (HIV) infection and multidrug-resistant tuberculosis (MDR-TB). Treatment outcomes among MDR-TB patients registered across the globe have been poor, partly due to high loss-to-follow-up. To address this challenge, MDR-TB patients in Nigeria are hospitalized during the intensive-phase(IP) of treatment (first 6-8 months) and are provided with a package of care including standardized MDR-TB treatment regimen, antiretroviral therapy (ART) and cotrimoxazole prophylaxis (CPT) for HIV-infected patients, nutritional and psychosocial support. In this study, we report the end-IP treatment outcomes among them.


Files in this item

Thumbnail
Name:
Oladimeji O et al-2014-Intensive ...
Size:
552.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record